J H Rex

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. pmc Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole
    J H Rex
    Department of Internal Medicine, University of Texas Medical School, Houston 77030, USA
    J Clin Microbiol 34:816-7. 1996
  2. ncbi Systematic root cause analysis of adverse drug events in a tertiary referral hospital
    J H Rex
    Hermann Hospital, Houston, TX, USA
    Jt Comm J Qual Improv 26:563-75. 2000
  3. pmc Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
    J H Rex
    Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston 77030, USA
    Antimicrob Agents Chemother 42:129-34. 1998
  4. ncbi Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America
    J H Rex
    Dept of Internal Medicine, Center for the Study of Emerging and Re Emerging Pathogens, University of Texas Medical School, Houston, TX 77030, USA
    Clin Infect Dis 30:662-78. 2000
  5. pmc Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
    S Arikan
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    J Clin Microbiol 37:3946-51. 1999
  6. pmc Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991
    M Lozano-Chiu
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    J Clin Microbiol 37:1625-7. 1999
  7. pmc Treatment of murine fusariosis with SCH 56592
    M Lozano-Chiu
    Department of Internal Medicine, University of Texas Medical School, Houston 77030, USA
    Antimicrob Agents Chemother 43:589-91. 1999
  8. pmc Antifungal susceptibility testing: practical aspects and current challenges
    J H Rex
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    Clin Microbiol Rev 14:643-58, table of contents. 2001
  9. pmc Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies
    M Lozano-Chiu
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas, USA
    J Clin Microbiol 36:2817-22. 1998
  10. pmc Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome
    M A Ghannoum
    Division of Infectious Diseases, Department of Internal Medicine, Harbor University of California, Los Angeles, USA
    J Clin Microbiol 34:489-95. 1996

Detail Information

Publications26

  1. pmc Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole
    J H Rex
    Department of Internal Medicine, University of Texas Medical School, Houston 77030, USA
    J Clin Microbiol 34:816-7. 1996
    ..These QC ranges are 0.064 to 0.25 micrograms/ml for both ketoconazole and itraconazole against C. parapsilosis ATCC 22019 and 0.125 to 0.5 micrograms/ml for both ketoconazole and itraconazole against C. krusei ATCC 6258...
  2. ncbi Systematic root cause analysis of adverse drug events in a tertiary referral hospital
    J H Rex
    Hermann Hospital, Houston, TX, USA
    Jt Comm J Qual Improv 26:563-75. 2000
    ..As many ADEs are preventable, identification and modification of systems and processes that permit ADEs has the potential to reduce the rate of ADEs...
  3. pmc Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
    J H Rex
    Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston 77030, USA
    Antimicrob Agents Chemother 42:129-34. 1998
    ..Minor variations in the M27-A endpoint criterion are thus required to optimize the in vitro-in vivo correlation for isolates that demonstrate significant trailing growth when tested against fluconazole...
  4. ncbi Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America
    J H Rex
    Dept of Internal Medicine, Center for the Study of Emerging and Re Emerging Pathogens, University of Texas Medical School, Houston, TX 77030, USA
    Clin Infect Dis 30:662-78. 2000
    ..g., some bone-marrow transplant recipients) or who receive a solid-organ transplant (e.g., some liver transplant recipients) have a sufficient risk of invasive candidiasis to warrant prophylaxis...
  5. pmc Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
    S Arikan
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    J Clin Microbiol 37:3946-51. 1999
    ..solani were high. RPMI was the most efficient medium for detection of itraconazole-resistant isolates, followed by RPMI-2. While the significance remains unclear, AM3 lowered the MICs, particularly those of amphotericin B...
  6. pmc Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991
    M Lozano-Chiu
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    J Clin Microbiol 37:1625-7. 1999
    ..Understanding the implications of these differences will require testing in an in vivo system...
  7. pmc Treatment of murine fusariosis with SCH 56592
    M Lozano-Chiu
    Department of Internal Medicine, University of Texas Medical School, Houston 77030, USA
    Antimicrob Agents Chemother 43:589-91. 1999
    ..The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani...
  8. pmc Antifungal susceptibility testing: practical aspects and current challenges
    J H Rex
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    Clin Microbiol Rev 14:643-58, table of contents. 2001
    ..against (perhaps) itraconazole. Expanding the range of useful testing procedures is the current focus of research in this area...
  9. pmc Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies
    M Lozano-Chiu
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas, USA
    J Clin Microbiol 36:2817-22. 1998
    ..Reading of the results after 48 h of incubation was required for testing in broth by the M27-A method, while the MIC could be determined after either 48 or 72 h when the agar diffusion method was used...
  10. pmc Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome
    M A Ghannoum
    Division of Infectious Diseases, Department of Internal Medicine, Harbor University of California, Los Angeles, USA
    J Clin Microbiol 34:489-95. 1996
    ....
  11. ncbi International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
    L Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School Houston, 6431 Fannin MSB 2 112, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 24:654-61. 2005
    ..Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia. Large-scale, randomized, controlled trials are warranted...
  12. pmc Differential antifungal activity of isomeric forms of nystatin
    L Ostrosky-Zeichner
    Laboratory of Mycology Research, Division of Infectious Diseases, Department of Internal Medicine, University of Texas Houston Medical School, 6431 Fannin, Houston, TX 77030, USA
    Antimicrob Agents Chemother 45:2781-6. 2001
    ..Both MIC measurements and time-kill analysis suggest that peak 2 has considerably less activity, if any at all, against Candida spp. Peak 2 may serve as a reservoir for peak 1...
  13. pmc In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates
    S Arikan
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 45:327-30. 2001
    ..While MICs increased inconsistently when the incubation time was prolonged, MEC appeared as a stable and potentially relevant endpoint in testing in vitro caspofungin activity...
  14. ncbi Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses
    J H Rex
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, TX, USA
    Clin Infect Dis 33:95-106. 2001
    ..Therefore, there is a need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses, and this article summarizes the possible strategies in this area...
  15. ncbi Prophylactic antifungal therapy in the intensive care unit
    J H Rex
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Re Emerging Pathogens, University of Texas Medical School, Houston, TX 77030, USA
    Clin Infect Dis 32:1191-200. 2001
    ..Investigations are needed to define and prove the utility of predictive tools for the identification of patients in the ICU who would benefit from prophylaxis...
  16. ncbi Voriconazole salvage treatment of invasive candidiasis
    L Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Houston Medical School, 6431 Fannin, JFB 1 728, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 22:651-5. 2003
    ..Voriconazole has promise as a salvage agent for the treatment of invasive candidiasis, even in the settings of previous azole therapy and infection due to Candida krusei...
  17. ncbi Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting
    L Ostrosky-Zeichner
    University of Texas Health Science Center at Houston, 6431 Fannin, MSB 2 112, Houston, TX 77030, USA
    Eur J Clin Microbiol Infect Dis 26:271-6. 2007
    ..36, sensitivity 0.34, specificity 0.90, positive predictive value 0.01, and negative predictive value 0.97. The rule may identify patients at high risk of invasive candidiasis...
  18. pmc Does one voriconazole breakpoint suit all Candida species?
    Maiken Cavling Arendrup
    J Clin Microbiol 45:2093; author reply 2094. 2007
  19. pmc Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints
    M A Pfaller
    Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    J Clin Microbiol 44:819-26. 2006
    ..The corresponding disk test breakpoints are as follows: S, > or = 17 mm; SDD, 14 to 16 mm; and R, < or = 13 mm...
  20. ncbi Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
    B J Kullberg
    Nijmegen University Centre for Infectious Diseases, Department of Internal Medicine 484, Radboud University Nijmegen Medical Centre 541, PO Box 9101, 6500 HB Nijmegen, Netherlands
    Lancet 366:1435-42. 2005
    ..This multicentre, randomised, non-inferiority study compared voriconazole with a regimen of amphotericin B followed by fluconazole for the treatment of candidaemia in non-neutropenic patients...
  21. pmc Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints
    M A Pfaller
    Department of Pathology, 200 Hawkins Drive, University of Iowa, Iowa City, IA 52242 1009, USA
    J Clin Microbiol 46:2620-9. 2008
    ..Subsequently, the isolates should be submitted to a reference laboratory that will confirm the results by using a CLSI reference dilution method...
  22. ncbi Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EU
    M Cuenca-Estrella
    Instituto de Salud Carlos III, Majadahonda, Spain
    Clin Microbiol Infect 9:467-74. 2003
    ..This standard is based on the M27-A procedure of the National Committee for Clinical Laboratory Standards (NCCLS), but incorporates several modifications, including spectrophotometric growth-dependent endpoint reading...
  23. ncbi Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults
    J H Rex
    Leukemia 16:1197-9. 2002
  24. ncbi Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus
    S Ascioglu
    Clin Infect Dis 34:7-14. 2002
    ..quot; The definitions are intended for use in the context of clinical and/or epidemiological research, not for clinical decision making...
  25. ncbi Lipid-based antifungal agents: current status
    S Arikan
    Mycology Unit, Department of Microbiology and Clinical Microbiology, Hacettepe University Medical School, Ankara, 06100, Turkey
    Curr Pharm Des 7:393-415. 2001
    ..Advances in technology of liposomes and other lipid formulations have provided promising new tools for management of fungal infections...
  26. pmc Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization
    M A Pfaller
    Department of Pathology and Epidemiology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Clin Microbiol Rev 17:268-80. 2004
    ..Proposed methods for fungal time-kill determinations and minimal fungicidal concentration determinations are also discussed...